These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26081314)

  • 1. Second episode of near-fatal angioedema in a patient treated with everolimus.
    Andersen LK; Jensen JE; Bygum A
    Ann Allergy Asthma Immunol; 2015 Aug; 115(2):152-3. PubMed ID: 26081314
    [No Abstract]   [Full Text] [Related]  

  • 2. [Everolimus and azoospermia, a causal relationship? About one case in a renal transplant patient].
    Wetzstein M; Weestel PF; Choukroun G
    Nephrol Ther; 2014 Feb; 10(1):44-5. PubMed ID: 24374233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study.
    Potena L; Bianchi IG; Magnani G; Masetti M; Coccolo F; Fallani F; Russo A; Grigioni F; Branzi A; Ponticelli C
    Transplantation; 2010 Jan; 89(2):263-5. PubMed ID: 20098293
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema.
    Fuchs U; Zittermann A; Berthold HK; Tenderich G; Deyerling KW; Minami K; Koerfer R
    Transplantation; 2005 Apr; 79(8):981-3. PubMed ID: 15849555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
    Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
    Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [67-year-old patient with speech disorder and dysphagia].
    Er F; Nia AM; Erdmann E
    Dtsch Med Wochenschr; 2008 Nov; 133(47):2463-4. PubMed ID: 19006046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate.
    Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
    Transplant Proc; 2010 Apr; 42(3):938-9. PubMed ID: 20430209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus.
    Pratap B; Abraham G; Srinivas CN; Bhaskar S
    Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):609-12. PubMed ID: 17951952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.
    Ferraresso M; Belingheri M; Ginevri F; Murer L; Dello Strologo L; Cardillo M; Parodi A; Ghirardo G; Guzzo I; Innocente A; Ghio L
    Pediatr Transplant; 2014 Jun; 18(4):350-6. PubMed ID: 24802342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
    Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching immunosuppressive drugs in kidney transplant recipients: "show me the evidence".
    Ansari MJ; Sayegh MH
    Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):149-52. PubMed ID: 16903619
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference.
    Rothenburger M; Zuckermann A; Bara C; Hummel M; Strüber M; Hirt S; Lehmkuhl H;
    J Heart Lung Transplant; 2007 Apr; 26(4):305-11. PubMed ID: 17403469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
    Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
    J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.
    Lorber MI; Ponticelli C; Whelchel J; Mayer HW; Kovarik J; Li Y; Schmidli H
    Clin Transplant; 2005 Apr; 19(2):145-52. PubMed ID: 15740547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.